财中社1月17日电泰达生物(08189)发布公告,宣布与配售代理中泰国际证券有限公司签署了配售协议,计划配售最多2.39亿股股份,配售价格为每股0.265港元。此次配售股份相当于公司现有已发行股本的约12.64%,若所有股份均被配售,预计所得款项总额约为6344万港元,扣除佣金及其他开支后,净额约为6300万港元。
公告中提到,配售价格较配售协议日期在联交所的收市价折让约18.46%,同时较最近五个交易日的平均收市价折让约13.96%。配售股份将根据股东周年大会上授予董事的一般授权进行发售,董事认为配售事项将扩大公司的股东基础和资本基础,符合公司及股东的整体利益。公司计划利用募集资金与合作伙伴共同新设公司,购买医疗健康软件平台,以提升其在医疗养老业务的服务能力和水平。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.